Compare TKLF & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKLF | NRSN |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | Japan | Israel |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 14.2M |
| IPO Year | 2020 | 2021 |
| Metric | TKLF | NRSN |
|---|---|---|
| Price | $1.50 | $3.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $97.33 |
| AVG Volume (30 Days) | 8.2K | ★ 124.8K |
| Earning Date | 07-10-2026 | 09-25-2026 |
| Dividend Yield | ★ 15.87% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.43 | $0.25 |
| 52 Week High | $3.77 | $7.50 |
| Indicator | TKLF | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 30.88 | 51.49 |
| Support Level | N/A | $0.63 |
| Resistance Level | $2.43 | $7.50 |
| Average True Range (ATR) | 0.09 | 0.85 |
| MACD | -0.01 | -0.37 |
| Stochastic Oscillator | 18.08 | 10.58 |
Tokyo Lifestyle Co Ltd is a retailer and wholesaler of Japanese beauty and health products, sundry products, electronic products, and other products. It sells its products through directly operated physical stores, online stores, and franchise stores and wholesale customers. It operates through directly operated physical stores, online stores and services, and franchise stores and wholesale customers segments, with the franchise stores and wholesale customers segment generating maximum revenue. Geographically, it generates maximum revenue from Hong Kong.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.